
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge, focused on developing TCR-based therapeutics for cancer and autoimmune diseases. Utilizing their proprietary OpTiMus® platform, they create unique, antigen-specific human TCRs aimed at transforming cancer treatment. The company combines expertise in mouse genome engineering, biopharmaceutical development, and machine learning, fostering a culture of innovation and collaboration. With a strong commitment to scientific excellence, T-Therapeutics is positioned to reshape the clinical landscape for patients.

T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge, focused on developing TCR-based therapeutics for cancer and autoimmune diseases. Utilizing their proprietary OpTiMus® platform, they create unique, antigen-specific human TCRs aimed at transforming cancer treatment. The company combines expertise in mouse genome engineering, biopharmaceutical development, and machine learning, fostering a culture of innovation and collaboration. With a strong commitment to scientific excellence, T-Therapeutics is positioned to reshape the clinical landscape for patients.
Headquarters: Cambridge, UK (Granta Park)
Technology: OpTiMus® fully humanized TCR mouse platform
Focus: TCR-based therapeutics for cancer and autoimmune diseases
Founded: 2022
Notable investors: Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent, Business Growth Fund
Cancer and autoimmune disease therapeutics development using T cell receptor-based approaches.
2022
Biotechnology
£48,000,000
Company announced a £48M Series A on 15 November 2023.
32,000,000
Dealroom lists a Series A of $32.0M in Nov 2025 and company communications indicate additional investors (Tencent, Business Growth Fund) increasing round totals.
“Backed by multiple blue-chip life sciences investors including Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital and Sanofi Ventures; later participation noted from Tencent and Business Growth Fund.”
About the Company
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge. The company was created to harness the power of T cell biology, to create safe and effective treatments for cancer and autoimmune disease. T-Therapeutics’ experienced team combines world-leading expertise in mouse genome engineering, single cell genomics, biopharmaceutical drug development, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
T-Therapeutics is developing ‘optimal’ TCR therapeutics using its proprietary OpTiMus® discovery platform, that provides an almost unlimited source of unique, antigen-specific human TCRs. The company is developing a pipeline of first-in-class drugs that are intended to become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.
Senior Scientist – Analytical Development – Protein Sciences
We are seeking an experienced, highly motivated Senior Scientist – Analytical Development to join our Protein Sciences Team. The ideal candidate will bring extensive expertise in Mass Spectrometry (LC-MS/MS) for protein characterisation and a strong background in developing and implementing analytical methods to support the advancement of preclinical biologics programmes.
This role will lead the development of mass spectrometry-based methods and as well as other characterisation assays for biologics, while also overseeing outsourced methods development and phase appropriate validation to support regulatory submissions.
In this role you will be responsible for:
Qualifications and requirements:
| Company |
|---|